文献速递眼底病与葡萄膜炎

Faricimab双靶点抑制Ang-2与VEGF-A治疗糖尿病性黄斑水肿的BOULEVARD 2期随机试验

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
PubMed 文献 · Ophthalmology · 2019-03-21

BOULEVARD 2期随机双盲多中心研究纳入229例糖尿病性黄斑水肿(DME)患者,比较Faricimab(同时抑制Ang-2和VEGF-A)与雷珠单抗的疗效与安全性。初治患者中6.0 mg Faricimab较雷珠单抗在24周时BCVA多提高3.6个字母(P=0.03),并呈剂量依赖性降低CST、改善DRSS评分及延长再治疗时间,未发现新的安全信号。

要点

  • 初治DME患者中6.0 mg Faricimab较雷珠单抗24周BCVA多 gain 3.6字母(P=0.03)
  • Faricimab呈剂量依赖性降低CST、改善DRSS评分并延长再治疗时间
  • Faricimab未显示新的或非预期安全信号

核心结论

  • BOULEVARD试验达到主要终点,初治DME患者中Faricimab在24周BCVA增益统计显著优于雷珠单抗。
  • CST降低、DRSS评分改善及延长的再治疗时间支持主要结局,提示同时抑制Ang-2和VEGF-A对DME患者有益。

研究设计与样本

  • 前瞻性、随机、活性对照、双盲、多中心2期研究,在美国59个中心开展(NCT02699450)。
  • 纳入229例患者(168例抗VEGF初治,61例既往接受抗VEGF治疗),年龄≥18岁,中心累及DME,BCVA 73至24个ETDRS字母,CST≥325 μm。
  • 初治患者按1:1:1随机接受玻璃体腔注射6.0 mg Faricimab、1.5 mg Faricimab或0.3 mg雷珠单抗;既往治疗患者按1:1随机接受6.0 mg Faricimab或0.3 mg雷珠单抗。
  • 每月给药至第20周,随后观察至第36周评估耐久性;预设主要结局为初治患者第24周BCVA较基线平均变化(Faricimab vs 雷珠单抗)。

主要发现

  • 初治患者中6.0 mg Faricimab、1.5 mg Faricimab和0.3 mg雷珠单抗分别使BCVA较基线平均提高13.9、11.7和10.3个ETDRS字母。
  • 6.0 mg Faricimab较雷珠单抗BCVA增益多3.6个字母,差异有统计学意义(P=0.03)。
  • 两个患者人群中,Faricimab均呈剂量依赖性降低CST、改善DRSS评分,并在观察期内较雷珠单抗延长再治疗时间。
  • Faricimab未显示新的或非预期安全信号。

关键数值与推荐

  • 主要终点:初治患者第24周BCVA较基线平均变化,6.0 mg Faricimab vs 0.3 mg雷珠单抗差异3.6个字母(P=0.03)。
  • 关键次要/探索性指标包括CST、DRSS评分及以再治疗时间评估的耐久性。

临床怎么用

  • 对于抗VEGF初治的DME患者,Faricimab双靶点抑制在24周视力增益上优于雷珠单抗,且可能延长再治疗间隔。
  • Faricimab呈剂量依赖性形态学改善(CST降低、DRSS评分改善),支持其用于DME治疗。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME). DESIGN: The BOULEVARD trial (ClinicalTrials.gov identifier, NCT02699450) was a prospective, randomized, active comparator-controlled, double-masked, multicenter, phase 2 study conducted at 59 sites in the United States. PARTICIPANTS: The trial enrolled patients 18 years of age or older with center-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) of 325 μm or more. METHODS: Anti-VEGF treatment-naïve patients were randomized 1:1:1 to intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibizumab, and patients previously treated with anti-VEGF were randomized 1:1 to 6.0 mg faricimab or 0.3 mg ranibizumab. Patients were dosed monthly for 20 weeks, followed by an observation period up to week 36 to assess durability. MAIN OUTCOME MEASURES: The prespecified primary outcome measure was mean change in BCVA from baseline at week 24 for faricimab versus ranibizumab in treatment-naïve patients. Key secondary and exploratory outcome measures included CST, Diabetic Retinopathy Severity Scale (DRSS) score, and durability as assessed by time to re-treatment. RESULTS: The trial enrolled 229 patients (168 treatment-naïve and 61 previously treated with anti-VEGF). In treatment-naïve patients, 6.0 mg faricimab, 1.5 mg faricimab, and 0.3 mg ranibizumab resulted in mean improvements of 13.9, 11.7, and 10.3 ETDRS letters from baseline, respectively. The 6.0-mg faricimab dose demonstrated a statistically significant gain of 3.6 letters over ranibizumab (P = 0.03). In both patient populations, faricimab resulted in dose-dependent reductions in CST, improvements in DRSS score, and longer time to re-treatment during the observation period compared with ranibizumab. Faricimab showed no new or unexpected safety signals. CONCLUSIONS: The BOULEVARD trial met its primary end point; faricimab demonstrated statistically superior visual acuity gains versus ranibizumab at week 24 in treatment-naïve patients. Central subfield thickness reduction, DRSS score improvement, and extended durability outcomes support the primary outcome. These findings suggest the benefit of simultaneous inhibition of angiopoietin-2 and VEGF-A with faricimab for patients with DME.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Sahni J, Patel SS, Dugel PU, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019. PMID: 30905643. doi:10.1016/j.ophtha.2019.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。